The Application of CRISPR/Cas9 in Cancer Immunotherapy
DOI:
https://doi.org/10.61173/v3m7t566Keywords:
CRISPR, Cas9, cancer immunotherapy, oncolytic virotherapy, CAR-T therapyAbstract
Currently, Cancer is the number one killer of human health. The death rate from cancer is increasing year over year as the population ages and grows, particularly since 2019, when there were almost 10 million cases globally recorded by the World Health Organization every year. In light of this trend, it is imperative to continue developing medications and to update and iterate on anti-cancer therapeutic technologies. CAR-T cell therapy, microphage-based therapy, oncolytic virotherapy, and checkpoint blockade therapy are the most popular cancer treatments, but a few patients still cannot tolerate these therapies. A post-optimized strategy is to use gene editing to alter the characteristics of cancer treatment. New therapeutic options for the treatment of complex disorders have become available with the development of CRISPR/Cas9 gene editing technology in recent years. This method is widely used in market research for gene knockdown, endogenous gene expression, and chromosome locus markers because of its accuracy and efficiency in processing harmful gene fragments. Also, it is extremely valuable from a medical standpoint when researching immunomodulator resistance. Despite its great potential, there remain concerns over the technology’s usefulness and efficacy and negative prognostic reactions. This review primarily focuses on the current use of CRISPR/Cas9 in cancer immunotherapies.
References
[1] Ferlay J., Laversanne M., Ervik M., et al. Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, 2020. Accessed on June 13, 2021.
[2] Xiao Y., Luo M., Hayes R.P., Kim J., Ng S., Ding F., Liao M., Ke A. Structure basis for directional R-loop formation and substrate handover mechanisms in type I CRISPR-Cas system. Cell. 2017;170:48-60.e11.
[3] Makarova KS, Haft DH, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 2011;9(6):467–477.
[4] Yuan M., Webb E., Lemoine N.R., Wang Y.J.V. CRISPR- Cas9 as a powerful tool for efficient creation of oncolytic viruses. Viruses. 2016;8:72.
[5] Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 2014;513:569–73.
[6] Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II Clinical Trial of a Granulocyte- Macrophage Colony-Stimulating Factor-Encoding, Second- Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. J Clin Oncol (2009) 27:5763–71.
[7] Jager L., Ehrhardt A. Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum Gene Ther. 2009;20:883–96.
[8] Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An Adenovirus Mutant That Replicates Selectively in P53-Deficient Human Tumor Cells. Sci (1996) 274(5286):373-6.
[9] Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B Gene-Attenuated Adenovirus, Causes Tumor-Specific Cytolysis and Antitumoral Efficacy That Can Be Augmented by Standard Chemotherapeutic Agents. Nat Med (1997) 3(6):639–45.
[10] Wieder T, Eigentler T, Brenner E, Röcken M. Immune Checkpoint Blockade Therapy. J Allergy Clin Immunol (2018) 142(5):1403–14.
[11] Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR- Cas9-Mediated Disruption of PD-1 on Human T Cells for Adoptive Cellular Therapies of EBV-Positive Gastric Cancer. Oncoimmunol (2016) 6(1):e1249558.
[12] Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med (2014) 371(16):1507– 17.
[13] Yang Y, Jacoby E, Fry TJ. Challenges and Opportunities of Allogeneic Donor-Derived CAR T Cells. Curr Opin Hematol (2015) 22(6):509–15.
[14] Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang C-H, Murata K, Sugata K, Saijo H, Matsunaga Y. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8(7):926–936.
[15] Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, and Zhu X. Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther. 2019;30(4):446–458.
[16] Inagaki K, Yamao T, Noguchi T, Matozaki T, Fukunaga K, Takada T, et al. SHPS-1 Regulates Integrin-Mediated Cytoskeletal Reorganization and Cell Motility. EMBO J (2000) 19(24):6721–31.
[17] Zhao XW, van Beek EM, Schornagel K, van der Maaden H, Van Houdt M, Otten MA, et al. CD47-signal Regulatory Protein-α (Sirpα) Interactions Form a Barrier for Antibody- Mediated Tumor Cell Destruction. Proc Natl Acad Sci USA (2011) 108:18342–7.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
